These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 34043191)

  • 1. Measurement of GCase Activity in Cultured Cells.
    Shojima Y; Ogata J; Tsunemi T; Imai Y; Hattori N
    Methods Mol Biol; 2021; 2322():47-52. PubMed ID: 34043191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies.
    Johnson PH; Weinreb NJ; Cloyd JC; Tuite PJ; Kartha RV
    Mol Genet Metab; 2020 Feb; 129(2):35-46. PubMed ID: 31761523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2 - Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease.
    Dobert JP; Bub S; Mächtel R; Januliene D; Steger L; Regensburger M; Wilfling S; Chen JX; Dejung M; Plötz S; Hehr U; Moeller A; Arnold P; Zunke F
    Adv Sci (Weinh); 2024 Jul; 11(25):e2401641. PubMed ID: 38666485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocerebrosidase dysfunction in neurodegenerative disease.
    Brooker SM; Krainc D
    Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine.
    Blandini F; Cilia R; Cerri S; Pezzoli G; Schapira AHV; Mullin S; Lanciego JL
    Mov Disord; 2019 Jan; 34(1):9-21. PubMed ID: 30589955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
    Mazzulli JR; Zunke F; Tsunemi T; Toker NJ; Jeon S; Burbulla LF; Patnaik S; Sidransky E; Marugan JJ; Sue CM; Krainc D
    J Neurosci; 2016 Jul; 36(29):7693-706. PubMed ID: 27445146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.
    Yang NY; Lee YN; Lee HJ; Kim YS; Lee SJ
    Biol Chem; 2013 Jul; 394(7):807-18. PubMed ID: 23435096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons.
    Gegg ME; Verona G; Schapira AHV
    Hum Mol Genet; 2020 Jun; 29(10):1716-1728. PubMed ID: 32391886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel glucosylceramide synthase inhibitor attenuates alpha synuclein pathology and lysosomal dysfunction in preclinical models of synucleinopathy.
    Cosden M; Jinn S; Yao L; Gretzula CA; Kandebo M; Toolan D; Hatcher NG; Ma L; Lemaire W; Adam GC; Burlein C; Minnick C; Flick R; Watt ML; Mulhearn J; Fraley M; Drolet RE; Marcus JN; Smith SM
    Neurobiol Dis; 2021 Nov; 159():105507. PubMed ID: 34509608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.
    Kim MJ; Jeon S; Burbulla LF; Krainc D
    Hum Mol Genet; 2018 Jun; 27(11):1972-1988. PubMed ID: 29579237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluorescence-Quenched Substrates for Quantitative Live Cell Imaging of Glucocerebrosidase Activity.
    Ashmus RA; Shen DL; Vocadlo DJ
    Methods Enzymol; 2018; 598():199-215. PubMed ID: 29306435
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Granek Z; Barczuk J; Siwecka N; Rozpędek-Kamińska W; Kucharska E; Majsterek I
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.
    Mazzulli JR; Xu YH; Sun Y; Knight AL; McLean PJ; Caldwell GA; Sidransky E; Grabowski GA; Krainc D
    Cell; 2011 Jul; 146(1):37-52. PubMed ID: 21700325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of α-synuclein and GBA1 in Parkinson's disease.
    Stojkovska I; Krainc D; Mazzulli JR
    Cell Tissue Res; 2018 Jul; 373(1):51-60. PubMed ID: 29064079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase.
    Kim MJ; Kim S; Reinheckel T; Krainc D
    JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38329128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.